Baseline Characteristics of Treated Patients (n = 38)
| Characteristic | Value |
| Age (y) | 66 (41–84) |
| Sex | |
| Male | 22 (58%) |
| Female | 16 (42%) |
| World Health Organization performance status | |
| 0 | 32 (84%) |
| 1 | 5 (13%) |
| 2 | 1 (3%) |
| Primary malignancy | |
| Colorectal | 23 (61%) |
| Breast | 4 (11%) |
| Cholangiocarcinoma | 4 (11%) |
| Neuroendocrine tumor | 2 (5%) |
| Uveal melanoma | 2 (5%) |
| Pancreatic cancer, gastric cancer, or thymoma | 3 (8%) |
| Time since diagnosis (mo) | 28 (4–95) |
| Occurrence of liver metastases | |
| Synchronous | 19 (50%) |
| Metachronous | 19 (50%) |
| Time since liver metastases (mo) | 18 (3–92) |
| Extrahepatic disease on 18F-FDG PET/CT | |
| Lung | 8/10 (80%) |
| Lymph node | 4/10 (40%) |
| Skeletal | 2/10 (20%) |
| Liver mass (kg) | 2.0 (1.2–4.0) |
| Tumor load on contrast-enhanced CT | |
| 0%–25% | 30 (79%) |
| 25%–50% | 6 (16%) |
| >50% | 2 (5%) |
Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as median followed by range in parentheses.